ArticleAsian journal of urology2026
Combining prostate-specific membrane antigen PET/CT with Memorial Sloan Kettering Cancer Center and Briganti 2012 nomograms enhances lymph node metastasis prediction in prostate cancer patients with a risk above 5.
Article in Asian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate intermediate- to high-risk prostate cancer patients with a predicted lymph node metastasis (LNM) probability over 5%, for whom pelvic lymph node dissection (PLND) is recommended, we assessed the ability of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) to reduce unnecessary PLND and its effectiveness when integrated with clinical nomograms like the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram and the Briganti 2012 nomogram. Methods: A total of 112 patients were selected. Univariate and multivariate logistic analyses were performed. The receiver operating characteristic curve and decision curve analysis were generated for assessing the incremental value of PET/CT diagnosis of LNM combined with the MSKCC and Briganti 2012 nomograms. The reduction in unnecessary PLND across risk thresholds based on the net benefit was further assessed, to evaluate the impact of adding PSMA PET/CT. Results: Surgical pathology confirmed LNM in 46 (41%) patients. PSMA PET/CT detected all metastases in patients with a 5%-25% LNM probability predicted by the MSKCC nomogram and three of four cases predicted by the Briganti 2012 nomogram in the same range. Multivariate logistic regression identified PSMA PET/CT as a significant predictor of LNM ( Conclusion: Integrating PSMA PET/CT with the MSKCC and Briganti 2012 nomograms improves LNM prediction in prostate cancer and significantly reduces unnecessary dissections in patients with a predicted LNM probability between 5% and 25%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.